Table 2.
Risk Factor | Hazard Ratio (95% CI) | P Value |
---|---|---|
Age ≥55 yr vs. <55 yr | 1.81 (1.20–2.73) | 0.004 |
IPSS risk group | ||
Intermediate-1 vs. low | 2.29 (1.69–3.11) | <0.001 |
Intermediate-2 vs. low | 3.45 (2.42–4.91) | <0.001 |
High vs. low | 5.85 (3.63–9.40) | <0.001 |
Mutational status | ||
TP53 mutation present vs. absent | 2.48 (1.60–3.84) | <0.001 |
EZH2 mutation present vs. absent | 2.13 (1.36–3.33) | <0.001 |
ETV6 mutation present vs. absent | 2.04 (1.08–3.86) | 0.03 |
RUNX1 mutation present vs. absent | 1.47 (1.01–2.15) | 0.047 |
ASXL1 mutation present vs. absent | 1.38 (1.00–1.89) | 0.049 |
The model was generated from a stepwise Cox regression model that included the International Prognostic Scoring System (IPSS) risk category (based on the percentage of blasts in bone marrow, the karyotype, and the number of cytopenias [see Table 2 in the Supplementary Appendix]), age, sex, and mutation status for genes that were mutated in 1% or more of the 428 samples for which the IPSS classification was recalculated. Age was included in the analysis as a categorical variable on the basis of a best-split algorithm showing a significant difference in overall survival between patients less than 55 years of age and those 55 years of age or older (see Table 8 in the Supplementary Appendix).